Live Chat

I CFD sono strumenti complessi e presentano un alto rischio di perdere soldi rapidamente a causa della leva finanziaria. Il 76,3% dei conti di clienti al dettaglio perde denaro facendo trading con i CFD con questo fornitore. Devi verificare se comprendi pienamente come funzionano i CFD e se puoi permetterti di correre il rischio elevato di perdere i tuoi soldi.

Close

Fai trading su Amgen AMGN

Grafico live di Amgen

Percezioni e opinioni

Weekly Search
Weekly
Daily
date Chiudi change variazione % Apertura Massimo Minimo

Markets.com news

French election results to drive European markets
markets.com Support Team 2024 Jul 04, 21:00

La prossima settimana: I risultati delle elezioni francesi saranno chiave per i mercati europei

Forex Indici
Macron calls snap election, riles markets
markets.com Support Team 2024 Jun 29, 21:00

La prossima settimana: La Francia scatenerà una crisi dell'euro?

CPI
Businessman pointing hologram online banking icon.
markets.com Support Team 2024 Jun 20, 16:00

La prossima settimana: Una carrellata di dati e uno sguardo all’inflazione

Forex Indici
RBA, SNB, Bank of England rate decisions due next week
markets.com Support Team 2024 Jun 13, 21:00

La prossima settimana: RBA e Bank of England - status quo o cambio all’orizzonte?

Forex Indici

Informazioni

Spread

1.72

Spread (%)

0.6479 %

Leva

1:5

Interesse overnight acquisto

-0.0597 %

Interesse overnight vendita

-0.0292 %

Valuta

USD

Orari di trading

Markets closed

Martedì

14:31 - 20:59

Lunedì

14:31-20:59

Mercoledì

14:31-20:59

Giovedi

14:31-20:59

Venerdì

14:31-20:59

Conto economico

Apertura

---

Chiusura precedente

---

Massimo/Minimo di 52 settimane

--- – ---

Capitalizzazione di mercato

141908705280

Azioni in circolazione

537532992

Data delle trimestrali (prossima)

1999-11-22

instr__dividend_date

2025-03-07

instr__ex_dividend_date

2025-02-14

instr__forward_annual_dividend_rate

9.52

instr__forward_annual_dividend_yield

0.0361

EPS

7.84

Azioni in circolazione

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Scopri di più su questo strumento

Strumenti correlati
Trustpilot
Live Chat